Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NIRSEVIMAB-ALIP Cause Incorrect dose administered? 80 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 80 reports of Incorrect dose administered have been filed in association with NIRSEVIMAB-ALIP. This represents 10.2% of all adverse event reports for NIRSEVIMAB-ALIP.

80
Reports of Incorrect dose administered with NIRSEVIMAB-ALIP
10.2%
of all NIRSEVIMAB-ALIP reports
0
Deaths
2
Hospitalizations

How Dangerous Is Incorrect dose administered From NIRSEVIMAB-ALIP?

Of the 80 reports, 2 (2.5%) required hospitalization.

Is Incorrect dose administered Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NIRSEVIMAB-ALIP. However, 80 reports have been filed with the FAERS database.

What Other Side Effects Does NIRSEVIMAB-ALIP Cause?

Drug ineffective (173) Respiratory syncytial virus bronchiolitis (135) Bronchiolitis (83) Respiratory syncytial virus infection (76) Pyrexia (54) Cough (45) Respiratory syncytial virus test positive (36) Extra dose administered (30) Product storage error (30) Rash (25)

What Other Drugs Cause Incorrect dose administered?

TIRZEPATIDE (23,301) ADALIMUMAB (14,000) DUPILUMAB (9,907) RANITIDINE (9,337) INSULIN LISPRO (8,318) ACETAMINOPHEN (5,316) DULAGLUTIDE (5,207) SECUKINUMAB (4,524) INSULIN GLARGINE (3,070) SOMATROPIN (2,772)

Which NIRSEVIMAB-ALIP Alternatives Have Lower Incorrect dose administered Risk?

NIRSEVIMAB-ALIP vs NITAZOXANIDE NIRSEVIMAB-ALIP vs NITISINONE NIRSEVIMAB-ALIP vs NITRAZEPAM NIRSEVIMAB-ALIP vs NITRENDIPINE NIRSEVIMAB-ALIP vs NITRIC

Related Pages

NIRSEVIMAB-ALIP Full Profile All Incorrect dose administered Reports All Drugs Causing Incorrect dose administered NIRSEVIMAB-ALIP Demographics